Wow ... “Combining immunotherapy agents is at the core of Bristol-Myers Squibb’s strategy, as it brings the opportunity to improve anti-tumor efficacy,” said Fouad Namouni, M.D. head of Oncology Development at Bristol-Myers Squibb. “We are excited to work with Advaxis to explore the potential of Opdivo and ADXS-DUAL to provide a potential new option for metastatic cervical cancer patients where there is a high unmet need.”
I am very excited that our constructs continue to develop and evolve, however somewhat frustrated about always being back at the start of another study without any significant cash upfront. Hopefully a mega deal is in the works instead of more dilution. The good news is that our platform continues to evolve; and that is what I believe someday possibly may ultimately lead to a cure.
News 
Market Data 
Discover 
